Stock Track | BeOne Medicines (ONC) Soars 9.54% Pre-Market Following Guggenheim's Buy Rating Reiteration

Stock Track

Sep 02

BeOne Medicines (ONC) stock is experiencing a significant surge in pre-market trading on Tuesday, soaring 9.54% following a positive analyst report. The sharp uptick comes as investors react to Guggenheim's reaffirmation of their bullish stance on the biopharmaceutical company.

Guggenheim analyst Michael Schmidt reiterated a Buy rating on BeOne Medicines on August 29, maintaining a price target of $365.00. This reaffirmation of confidence from a prominent Wall Street firm appears to have sparked renewed investor interest in the stock. The substantial price target suggests significant upside potential, which is likely contributing to the pre-market rally.

The market's strong reaction to the analyst's report underscores the weight that Wall Street opinions carry in the biopharmaceutical sector. Investors seem to be interpreting the maintained Buy rating and high price target as indicators of BeOne Medicines' strong fundamentals and growth prospects. As the trading day progresses, it will be interesting to see if the stock can maintain its momentum and if additional analysts weigh in on the company's outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1190123890"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190123890\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190123890?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190123890","market":"us","top_or_hot":-1,"title":"Stock Track | BeOne Medicines (ONC) Soars 9.54% Pre-Market Following Guggenheim's Buy Rating Reiteration","media":"Stock Track","content":"<p>BeOne Medicines (ONC) stock is experiencing a significant surge in pre-market trading on Tuesday, soaring 9.54% following a positive analyst report. The sharp uptick comes as investors react to Guggenheim's reaffirmation of their bullish stance on the biopharmaceutical company.</p>\n\n<p>Guggenheim analyst Michael Schmidt reiterated a Buy rating on BeOne Medicines on August 29, maintaining a price target of $365.00. This reaffirmation of confidence from a prominent Wall Street firm appears to have sparked renewed investor interest in the stock. The substantial price target suggests significant upside potential, which is likely contributing to the pre-market rally.</p>\n\n<p>The market's strong reaction to the analyst's report underscores the weight that Wall Street opinions carry in the biopharmaceutical sector. Investors seem to be interpreting the maintained Buy rating and high price target as indicators of BeOne Medicines' strong fundamentals and growth prospects. As the trading day progresses, it will be interesting to see if the stock can maintain its momentum and if additional analysts weigh in on the company's outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeOne Medicines (ONC) Soars 9.54% Pre-Market Following Guggenheim's Buy Rating Reiteration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeOne Medicines (ONC) Soars 9.54% Pre-Market Following Guggenheim's Buy Rating Reiteration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-02 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines (ONC) stock is experiencing a significant surge in pre-market trading on Tuesday, soaring 9.54% following a positive analyst report. The sharp uptick comes as investors react to Guggenheim's reaffirmation of their bullish stance on the biopharmaceutical company.</p>\n\n<p>Guggenheim analyst Michael Schmidt reiterated a Buy rating on BeOne Medicines on August 29, maintaining a price target of $365.00. This reaffirmation of confidence from a prominent Wall Street firm appears to have sparked renewed investor interest in the stock. The substantial price target suggests significant upside potential, which is likely contributing to the pre-market rally.</p>\n\n<p>The market's strong reaction to the analyst's report underscores the weight that Wall Street opinions carry in the biopharmaceutical sector. Investors seem to be interpreting the maintained Buy rating and high price target as indicators of BeOne Medicines' strong fundamentals and growth prospects. As the trading day progresses, it will be interesting to see if the stock can maintain its momentum and if additional analysts weigh in on the company's outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1190123890","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190123890","pubTimestamp":1756820087,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeOne Medicines (ONC) stock is experiencing a significant surge in pre-market trading on Tuesday, soaring 9.54% following a positive analyst report. The sharp uptick comes as investors react to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州"},"translate_title":"股票追踪|古根海姆重申买入评级后，BeOne Medicines(ONC)盘前飙升9.54%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1},"content_text":"BeOne Medicines (ONC) stock is experiencing a significant surge in pre-market trading on Tuesday, soaring 9.54% following a positive analyst report. The sharp uptick comes as investors react to Guggenheim's reaffirmation of their bullish stance on the biopharmaceutical company.\nGuggenheim analyst Michael Schmidt reiterated a Buy rating on BeOne Medicines on August 29, maintaining a price target of $365.00. This reaffirmation of confidence from a prominent Wall Street firm appears to have sparked renewed investor interest in the stock. The substantial price target suggests significant upside potential, which is likely contributing to the pre-market rally.\nThe market's strong reaction to the analyst's report underscores the weight that Wall Street opinions carry in the biopharmaceutical sector. Investors seem to be interpreting the maintained Buy rating and high price target as indicators of BeOne Medicines' strong fundamentals and growth prospects. As the trading day progresses, it will be interesting to see if the stock can maintain its momentum and if additional analysts weigh in on the company's outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}